Skip to main content
OpenTrials
Completed

NCT Number: NCT04920643

High-exchange ULTrafiltration to Enhance Recovery After Pediatric Cardiac Surgery

Malformations of the heart are common; 1.35 million infants are born each year with congenital heart disease. Many of these defects carry a considerable threat to the individual's quality of life as well as survival. Along with focused medical management, surgical repair remains a standard of care for more than 25,000 infants and children each year in the United States and Canada. The care of individuals with congenital heart disease is highly complex and has significant risks of morbidity and mortality. Most cardiac operations require the use of cardiopulmonary bypass (CPB, also known as the heart-lung machine) to safely access the inner chambers of the heart. CPB itself has been well documented to cause significant inflammation and hemodilution as the individual's blood is passed through a foreign circuit. This inflammatory response can lead to fluid overload, distributive shock and potential end-organ dysfunction in the heart, lungs, kidneys, brain, liver or bowels. These organ dysfunctions may culminate in post-operative low cardiac output syndrome (LCOS), prolonged ventilation time, prolonged intensive care unit (ICU) stay and can contribute to mortality.

Dampening the inflammatory response from CPB has been a focus of research interest for years. Intra-operative ultrafiltration has been used to remove excess fluids and filter off inflammatory cytokines during cardiac operations. Over 90% of children's heart centers in the world utilize some form of ultrafiltration (mostly some form of modified ultrafiltration), but there are wide variations in published ultrafiltration protocols (none of which are combination SBUF-SMUF in children). Ultimately, this project seeks to provide high-quality evidence that the immunologic and clinical effects of combination SBUF-SMUF are rate dependent. Therefore, a randomized study directly comparing a high-exchange SBUF-SMUF (60ml/kg/hr) and a low-exchange SBUF-SMUF (6ml/kg/hr) can identify which is the optimal ultrafiltration protocol to enhance post-operative clinical outcomes for this patient population. The expected data and results could be immediately applicable to improve recovery after heart surgery for infants and children across Canada and the rest of the world at large.

Completed

Looking for future studies?

Notify Me

Key information

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

IWK Health Centre

Halifax, Nova Scotia, Canada

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Congenital heart patients (2.5 - 15kg) have consented for a planned cardiac surgery procedure requiring cardiopulmonary bypass.
  • Parent or legal substitute decision-maker informed written consent to participate in the study.

Exclusion criteria

  • Patient or family refusal to participate.
  • Patient over 15kg (Fontan or Glenn patients will be considered up to 18kg)
  • No planned use of cardiopulmonary bypass
  • Isolated ASD repair
  • Known severe hematologic abnormality such as sick cell anemia, thalassemia, haemophilia A or B, von Willebrand disease or other.
  • Known genetic syndrome with severe neurologic or multi-organ abnormalities and immune dysfunction such as DiGeorge Syndrome, Trisomy 18 or 13, Noonan syndrome. (Trisomy 21 may be included in the study).
  • Known immunodeficiency syndrome or bone marrow pathology.
  • Severe liver or renal disease.

Treatment and study plan

Ultrafiltration

Procedure

Ultrafiltration is used during cardiac surgery with cardiopulmonary bypass to remove both fluid and small molecules such as inflammatory cytokines from the patient's circulation.

Primary outcomes

  1. Peak Vasoactive-Ventilation Renal Score

    Time frame: Up to 5 days

Secondary outcomes

  1. Vasoactive Inotrope Score

    Time frame: Up to 5 days

    Taken in time series at ICU admission, 0, 12, 24, 36, 48, 72, 96 and 120 hours.

  2. Ventilation Index

    Time frame: Up to 5 days

    Taken in time series at ICU admission, 0, 12, 24, 36, 48, 72, 96 and 120 hours.

  3. Oxygenation Index

    Time frame: Up to 5 days

    Taken in time series at ICU admission, 0, 12, 24, 36, 48, 72, 96 and 120 hours.

  4. Ventilation Time

    Time frame: Up to 28 days

  5. Ventilator Free Days

    Time frame: Up to 28 days

  6. Low Cardiac Output Syndrome

    Time frame: Up to 3 days

    Defined by any one of the following within the first 72 post-operative hours:

    • Lactate > 4mM with oxygen extraction >35% (SaO2 - ScvO2/ SaO2)
    • VIS > 15.0 with oxygen extraction >35% (SaO2 - ScvO2/ SaO2)
    • Mechanical circulatory support requirement
  7. Vasoplegic Shock

    Time frame: Up to 3 days

    Defined by any one of the following with the first 72 post-operative hours:

    • Lactate > 4mM with oxygen extraction <25% (SaO2 - ScvO2/ SaO2)
    • VIS > 15.0 with oxygen extraction <25% (SaO2 - ScvO2/ SaO2)
  8. Inotrope Dependence

    Time frame: Up to 2 days

    Vasoactive-inotrope score at 48 hours equal to or greater than that at ICU admission.

  9. Inotrope Free Days

    Time frame: Up to 28 days

  10. C-Reactive Protein Concentrations

    Time frame: Measured at 1 day

  11. Composite Outcome of mechanical circulatory support, acute renal failure, prolonged intubation and operative mortality.

    Time frame: Up to 30 days

  12. Cytokine Concentration (Patient Plasma)

    Time frame: Up to 1 day

    C3, C3a, C3b, C5, C5a, IL-1, IL1-Ra, IL-6, IL-10, TNF, CXCL-8 among others. The final selection of mediators will be subject to final pilot study results and assay availability. Taken at baseline, 0 hours and 24 hours after CPB.

  13. Loop Diuretic Use

    Time frame: Up to 7 days

    Total loop diuretic (mg/kg), measured in furosemide equivalents, during the first 7 post-operative days.

  14. Peak Vasoactive-Inotrope Score

    Time frame: Up to 5 days

  15. Peak Ventilation Index

    Time frame: Up to 5 days

  16. Peak Oxygenation Index

    Time frame: Up to 5 days

  17. Prolonged Intubation

    Time frame: Up to 28 days

    Mechanical ventilation for more than 7 days

  18. Inotrope Time

    Time frame: Up to 28 days

  19. Acute Kidney Injury

    Time frame: Up to 28 days

    KDIGO Criteria

  20. ICU Length of Stay

    Time frame: Up to 30 days

  21. Hospital Length of Stay

    Time frame: Up to 60 days

  22. Haptoglobin (Plasma)

    Time frame: Up to 1 day

  23. Complete blood count

    Time frame: Up to 5 days

  24. Lactate

    Time frame: Up to 5 days

    Measured by arterial blood gas (mM)

  25. Creatinine

    Time frame: Up to 5 days

    Blood Concentration (uM)

  26. Vasoactive-Ventilation Renal Score

    Time frame: Up to 5 days

    Taken in time series at ICU admission, 12, 24, 36, 48, 72, 96 and 120 hours.

Sponsors and collaborators

Lead sponsor

IWK Health Centre

Other

Registry information

Official study title

High-exchange ULTrafiltration to Enhance Recovery After Pediatric Cardiac Surgery (ULTRA): A Canadian Randomized Controlled Trial

Acronym: ULTRA

Important dates

Study start
2021
Primary completion
2025
Study completion
2025
First posted
Jun 10, 2021
Registry last updated
May 25, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.